

Frank P Vleggaar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3566562/publications.pdf>

Version: 2024-02-01

77
papers

5,160
citations

109137

35
h-index

85405

71
g-index

79
all docs

79
docs citations

79
times ranked

8302
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell Death Independent of Caspases: A Review. <i>Clinical Cancer Research</i> , 2005, 11, 3155-3162.	3.2	792
2	Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 490-499.	0.5	471
3	Global Histone Modifications Predict Prognosis of Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4358-4364.	0.8	257
4	Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1 α -ZEB1 axis. <i>Cancer Letters</i> , 2015, 359, 107-116.	3.2	251
5	Cathepsin B Mediates Caspase-Independent Cell Death Induced by Microtubule Stabilizing Agents in Non-Small Cell Lung Cancer Cells. <i>Cancer Research</i> , 2004, 64, 27-30.	0.4	204
6	TRAIL and cancer therapy. <i>Cancer Letters</i> , 2008, 263, 14-25.	3.2	153
7	Abnormal Microsomal Detoxification Implicated in Fanconi Anemia Group C by Interaction of the FAC Protein With NADPH Cytochrome P450 Reductase. <i>Blood</i> , 1998, 92, 3050-3056.	0.6	145
8	Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidylinositol-3 kinase pathways in non-small cell lung cancer cells. <i>International Journal of Cancer</i> , 2006, 118, 209-214.	2.3	142
9	CRM1-Mediated Nuclear Export Determines the Cytoplasmic Localization of the Antiapoptotic Protein Survivin. <i>Experimental Cell Research</i> , 2002, 275, 44-53.	1.2	139
10	TGF- β 2 as a therapeutic target in high grade gliomas – Promises and challenges. <i>Biochemical Pharmacology</i> , 2013, 85, 478-485.	2.0	133
11	EMT- and MET-related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunities. <i>Molecular Oncology</i> , 2017, 11, 860-877.	2.1	121
12	TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2103-2112.	1.9	111
13	Kahalalide F Induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling. <i>Molecular Pharmacology</i> , 2005, 68, 502-510.	1.0	107
14	The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastoma. <i>Biochemical Pharmacology</i> , 2016, 118, 1-8.	2.0	105
15	Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting. <i>Biochemical Pharmacology</i> , 2019, 160, 121-133.	2.0	99
16	Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1805, 123-140.	3.3	96
17	Toward a New Generation of Conditionally Replicating Adenoviruses: Pairing Tumor Selectivity with Maximal Oncolysis. <i>Human Gene Therapy</i> , 2002, 13, 485-495.	1.4	91
18	Conditionally Replicating Adenoviruses Kill Tumor Cells via a Basic Apoptotic Machinery-Independent Mechanism That Resembles Necrosis-Like Programmed Cell Death. <i>Journal of Virology</i> , 2004, 78, 12243-12251.	1.5	81

#	ARTICLE	IF	CITATIONS
19	Targeting apoptosis pathways in lung cancer. <i>Cancer Letters</i> , 2013, 332, 359-368.	3.2	79
20	Apoptosis and cancer stem cells: Implications for apoptosis targeted therapy. <i>Biochemical Pharmacology</i> , 2010, 80, 423-430.	2.0	78
21	TGF- β 2 Antibody Uptake in Recurrent High-Grade Glioma Imaged with ⁸⁹ Zr-Fresolimumab PET. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1310-1314.	2.8	78
22	Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. <i>Biochemical Pharmacology</i> , 2012, 83, 207-217.	2.0	68
23	Expression and localization of inhibitor of apoptosis proteins in normal human tissues. <i>Human Pathology</i> , 2006, 37, 78-86.	1.1	63
24	Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 363-372.	2.0	61
25	Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3 dependent invasion in resistant non-small cell lung cancer cells. <i>Journal of Cell Science</i> , 2012, 125, 4651-61.	1.2	57
26	MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ER α expression and AKT activation. <i>Cancer Letters</i> , 2017, 386, 65-76.	3.2	54
27	Two death-inducing human TRAIL receptors to target in cancer: Similar or distinct regulation and function?. <i>Biochemical Pharmacology</i> , 2014, 91, 447-456.	2.0	53
28	MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines. <i>Npj Breast Cancer</i> , 2018, 4, 20.	2.3	52
29	Resistance to Mitomycin C Requires Direct Interaction between the Fanconi Anemia Proteins FANCA and FANCG in the Nucleus through an Arginine-rich Domain. <i>Journal of Biological Chemistry</i> , 1999, 274, 34212-34218.	1.6	51
30	Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy. <i>Frontiers in Immunology</i> , 2019, 10, 1530.	2.2	51
31	ER stress and UPR activation in glioblastoma: identification of a noncanonical PERK mechanism regulating GBM stem cells through SOX2 modulation. <i>Cell Death and Disease</i> , 2019, 10, 690.	2.7	51
32	Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1046-1053.	1.9	47
33	Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: A small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation. <i>Experimental Cell Research</i> , 2007, 313, 1215-1224.	1.2	44
34	Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 535-542.	1.1	38
35	TGF- β 2 promotes microtubule formation in glioblastoma through thrombospondin 1. <i>Neuro-Oncology</i> , 2022, 24, 541-553.	0.6	38
36	Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2. <i>Experimental Cell Research</i> , 2004, 298, 535-548.	1.2	37

#	ARTICLE	IF	CITATIONS
37	MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 851-860.	2.2	37
38	Serum-Induced Differentiation of Glioblastoma Neurospheres Leads to Enhanced Migration/Invasion Capacity That Is Associated with Increased MMP9. <i>PLoS ONE</i> , 2015, 10, e0145393.	1.1	35
39	Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. <i>Cancer Gene Therapy</i> , 2004, 11, 539-546.	2.2	33
40	Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. <i>Proteomics - Clinical Applications</i> , 2007, 1, 598-604.	0.8	31
41	Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export. <i>Human Molecular Genetics</i> , 2005, 14, 1271-1281.	1.4	30
42	Loss of CD44 and SOX2 Expression is Correlated with a Poor Prognosis in Esophageal Adenocarcinoma Patients. <i>Annals of Surgical Oncology</i> , 2014, 21, 657-664.	0.7	30
43	Targeting FLIP and Mcl-1 using a combination of aspirin and Sorafenib sensitizes colon cancer cells to TRAIL. <i>Journal of Pathology</i> , 2013, 229, 410-421.	2.1	28
44	IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma. <i>Oncotarget</i> , 2018, 9, 15721-15731.	0.8	28
45	Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines. <i>Cancer Science</i> , 2010, 101, 440-447.	1.7	27
46	Subclassification of Newly Diagnosed Glioblastomas through an Immunohistochemical Approach. <i>PLoS ONE</i> , 2014, 9, e115687.	1.1	24
47	Comparative proteomics analysis of caspase-9-protein complexes in untreated and cytochrome c/dATP stimulated lysates of NSCLC cells. <i>Journal of Proteomics</i> , 2009, 72, 575-585.	1.2	23
48	The unfolded protein response as regulator of cancer stemness and differentiation: Mechanisms and implications for cancer therapy. <i>Biochemical Pharmacology</i> , 2021, 192, 114737.	2.0	21
49	CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 117, 152-158.	0.3	19
50	Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma. <i>Cell Reports</i> , 2018, 22, 3206-3216.	2.9	19
51	Cisplatin triggers apoptotic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner. <i>Experimental Cell Research</i> , 2003, 286, 381-395.	1.2	18
52	Subcellular localization of CrmA: identification of a novel leucine-rich nuclear export signal conserved in anti-apoptotic serpins. <i>Biochemical Journal</i> , 2003, 373, 251-259.	1.7	16
53	FANCD2 Expression in Advanced Non-Small-Cell Lung Cancer and Response to Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2005, 6, 250-254.	1.1	16
54	SK channel activation potentiates auranofin-induced cell death in glio- and neuroblastoma cells. <i>Biochemical Pharmacology</i> , 2020, 171, 113714.	2.0	16

#	ARTICLE	IF	CITATIONS
55	Physics of Brain Cancer: Multiscale Alterations of Glioblastoma Cells under Extracellular Matrix Stiffening. <i>Pharmaceutics</i> , 2022, 14, 1031.	2.0	16
56	Cloning and Analysis of the Mouse Fanconi Anemia Group A cDNA and an Overlapping Penta Zinc Finger cDNA. <i>Genomics</i> , 2000, 67, 273-283.	1.3	15
57	Normal expression of the Fanconi anemia proteins FAA and FAC and sensitivity to mitomycin C in two Patients with Seckel syndrome. , 1999, 83, 388-391.		14
58	The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma. <i>SpringerPlus</i> , 2014, 3, 495.	1.2	14
59	Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses. <i>Journal of Neuro-Oncology</i> , 2017, 131, 11-20.	1.4	14
60	GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma. <i>Digestive and Liver Disease</i> , 2015, 47, 73-80.	0.4	13
61	BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity. <i>Toxicology and Applied Pharmacology</i> , 2016, 295, 56-67.	1.3	13
62	The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1273-1283.	1.1	12
63	Understanding Lung Carcinogenesis from a Morphostatic Perspective: Prevention and Therapeutic Potential of Phytochemicals for Targeting Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5697.	1.8	12
64	TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cells. <i>BMC Cancer</i> , 2006, 6, 166.	1.1	11
65	Circulating miRNAs in patients with Barrett's esophagus, high-grade dysplasia and esophageal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1150-1156.	0.6	11
66	Three-dimensional culture models to study glioblastoma " current trends and future perspectives. <i>Current Opinion in Pharmacology</i> , 2021, 61, 91-97.	1.7	11
67	Do Fanconi anemia genes control cell response to cross-linking agents by modulating cytochrome P-450 reductase activity?. <i>Drug Resistance Updates</i> , 2000, 3, 211-215.	6.5	9
68	CD146 increases stemness and aggressiveness in glioblastoma and activates YAP signaling. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	9
69	Genotype analysis of the VNTR polymorphism in the <i>SMYD3</i> histone methyltransferase gene: Lack of correlation with the level of histone H3 methylation in NSCLC tissues or with the risk of NSCLC. <i>International Journal of Cancer</i> , 2008, 122, 1441-1442.	2.3	7
70	Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma. <i>Journal of Neuro-Oncology</i> , 2021, 153, 211-222.	1.4	7
71	A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic marker. <i>Lung Cancer</i> , 2021, 154, 13-22.	0.9	7
72	A real-time RT-PCR assay for the quantitative determination of adenoviral gene expression in tumor cells. <i>Journal of Virological Methods</i> , 2006, 133, 53-61.	1.0	6

#	ARTICLE	IF	CITATIONS
73	Necrosis binding of Ac-Lys0(IRDye800CW)-Tyr3-octreotate: a consequence from cyanine-labeling of small molecules. EJMML Research, 2021, 11, 47.	1.1	5
74	The Unfolded Protein Response Sensor PERK Mediates Stiffness-Dependent Adaptation in Glioblastoma Cells. International Journal of Molecular Sciences, 2022, 23, 6520.	1.8	4
75	MBRS-36. IDENTIFICATION OF TWO PROTEIN-SIGNALING STATES DELINEATING TRANSCRIPTIONALLY HETEROGENEOUS HUMAN MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i136-i136.	0.6	0
76	STEM-11. CD146/MCAM REGULATES MESENCHYMAL PROPERTIES, STEMNESS, RADIO-RESISTANCE AND YAP ACTIVITY IN GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi236-vi236.	0.6	0
77	Protein Replacement by Receptor-Mediated Endocytosis Corrects the Sensitivity of Fanconi Anemia Group C Cells to Mitomycin C. Blood, 1999, 93, 363-369.	0.6	0